Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?
- 8 February 2010
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 46 (10) , 1800-1807
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2009
- Comparing patients’ and their partners’ preferences for adjuvant chemotherapy in early breast cancerPatient Education and Counseling, 2008
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancerPsycho-Oncology, 2006
- Explaining Differences in Attitude Toward Adjuvant Chemotherapy Between Experienced and Inexperienced Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?Annals of Oncology, 2005
- Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site GroupJournal of Clinical Oncology, 2004
- Review of Determinants of Patients’ Preferences for Adjuvant Therapy in CancerJournal of Clinical Oncology, 2004
- Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile?The Lancet Oncology, 2001
- Age and Clinical Decision Making in Oncology PatientsJNCI: Journal of the National Cancer Institute, 1994